Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

NCT00387933 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Duke University

Collaborators